GH1 and acromegaly: Long-term follow-up of patients with acromegaly shows no increase in mortality risk in patients who maintain normalized IGF-I [89] (MQ), and improved rates of biochemical control in more recent years has been attributed, at least in part, to effective GH suppression with use of SRL therapy [90, 91] (LQ).